Drug to Treat PPID Clinical Signs Receives FDA Approval

  • Print
  • Email
  • Favorite
  • Share
  • Newsletters

Boehringer Ingelheim Vetmedica Inc. (BIVI), has received FDA approval to market Prascend (pergolide mesylate) for treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's disease.

To continue reading this article, become a member of TheHorse.com.

It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.

Sign In
Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners